Howard W. Robin - 09 Sep 2025 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
President & CEO, Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
09 Sep 2025
Net transactions value
-$311,214
Form type
4
Filing time
11 Sep 2025, 21:01:44 UTC
Previous filing
08 Sep 2025
Next filing
25 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ROBIN HOWARD W President & CEO, Director C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO Mark A. Wilson, Attorney-in-Fact 11 Sep 2025 0001206869

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale $94,836 -2,100 -3.7% $45.16 53,908 09 Sep 2025 Direct F1, F2
transaction NKTR Common Stock Sale $55,692 -1,200 -2.2% $46.41 52,708 09 Sep 2025 Direct F1, F3
transaction NKTR Common Stock Sale $102,388 -2,156 -4.1% $47.49 50,552 09 Sep 2025 Direct F1, F4
transaction NKTR Common Stock Sale $58,298 -1,210 -2.4% $48.18 49,342 09 Sep 2025 Direct F1, F5
holding NKTR Common Stock 28 09 Sep 2025 by spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $45.00 to $45.41 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F3 This transaction was executed in multiple trades at prices ranging from $46.05 to $46.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F4 This transaction was executed in multiple trades at prices ranging from $47.02 to $47.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F5 This transaction was executed in multiple trades at prices ranging from $48.00 to $48.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.